Oklahoma Medicaid Enters Value-Based Contract With Alkermes For Injectable ARISTADA

In August 2018, the Oklahoma Health Care Authority (OHCA) entered into a value-based purchasing agreement with Alkermes for the long-acting injectable antipsychotic ARISTADA® (aripiprazole lauroxil). ARISTADA is an FDA-approved, long-acting atypical antipsychotic that has a two-month dosing interval.

The agreement is the first after OHCA announced on June 28, 2018, that it had received federal approval from the Centers for Medicare & Medicaid Services (CMS) of its state plan amendment (SPA) proposal to adopt value-based or outcomes-based contracts with pharmaceutical companies. The contracts will tie the net costs of medications to successful clinical . . .